Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 11:9:754630.
doi: 10.3389/fcell.2021.754630. eCollection 2021.

Extracellular Vesicles as Innovative Treatment Strategy for Amyotrophic Lateral Sclerosis

Ke Wang  1 , Yu Li  1 , Chao Ren  1 , Yongjing Wang  1 , Wenshan He  1 , Yuan Jiang  1
Affiliations
Review

Extracellular Vesicles as Innovative Treatment Strategy for Amyotrophic Lateral Sclerosis

Ke Wang et al. Front Cell Dev Biol. .

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive and fatal motor neuron degenerative disease, and it is hard to diagnose in the early stage, and treatment means are limited, and the treatment effect is unsatisfactory. Therefore, exploring a new effective treatment strategy is urgently needed for ALS patients. Extracellular vesicles (EVs) are a heterogeneous group of natural membrane vesicles containing many bioactive substances, and they play important roles in the paracrine pathway and exhibit neuroprotection effects. A growing body of evidence shows that EVs have great application potential in diagnosis, treatment, and drug delivery in ALS, and they represent an innovative treatment strategy for ALS. In this review, we will briefly introduce the biogenesis of EVs and focus on discussing the role of EVs in ALS treatment to further enrich and boost the development of EVs as an innovative treatment strategy for ALS.

Keywords: amyotrophic lateral sclerosis; exosome-mimics; extracellular vesicles; plant EVs; treatment strategy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Schematic representation of EVs biogenesis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alvarez-Erviti L., Seow Y., Yin H., Betts C., Lakhal S., Wood M. J. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29 341–345. 10.1038/nbt.1807 - DOI - PubMed
    1. Andjus P., Kosanović M., Milićević K., Gautam M., Vainio S. J., Jagečić D., et al. (2020). Extracellular vesicles as innovative tool for diagnosis, regeneration and protection against neurological damage. Int. J. Mol. Sci. 21:6859. 10.3390/ijms21186859 - DOI - PMC - PubMed
    1. Armstrong J. P., Holme M. N., Stevens M. M. (2017). Re-Engineering extracellular vesicles as smart nanoscale therapeutics. ACS Nano 11 69–83. 10.1021/acsnano.6b07607 - DOI - PMC - PubMed
    1. Asai H., Ikezu S., Tsunoda S., Medalla M., Luebke J., Haydar T., et al. (2015). Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci. 18 1584–1593. 10.1038/nn.4132 - DOI - PMC - PubMed
    1. Banack S. A., Dunlop R. A., Cox P. A. (2020). An miRNA fingerprint using neural-enriched extracellular vesicles from blood plasma: towards a biomarker for amyotrophic lateral sclerosis/motor neuron disease. Open Biol. 10:200116. 10.1098/rsob.200116 - DOI - PMC - PubMed